MedDataX Logo

Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer

NCT00217815 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-07-15

No results posted yet for this study

Summary

The study hypothesis is that the addition of Mycograb to docetaxel will improve outcome in advanced carcinoma of the breast.

Conditions

  • Cancer of the Breast

Interventions

DRUG

Mycograb, Docetaxel

Sponsors & Collaborators

  • NeuTec Pharma

    lead INDUSTRY

Principal Investigators

  • Anna Pluzanska, MD · University of Lodz

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2006-10-31

Countries

  • Poland
  • Serbia

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00217815 on ClinicalTrials.gov